Ginkgo Bioworks reportedly explores $20B SPAC deal

Synthetic biology company Ginkgo Bioworks is toying with the idea of going public via a reverse merger with special-purpose acquisition company Soaring Eagle Acquisition Corp., Bloomberg has reported. The deal could value Ginkgo at more than $20 billion — more than five times what Ginkgo was valued at in late 2019, when it last raised venture capital.